This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APOP Cellect Biotechnology (APOP) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Cellect Biotechnology Stock (NASDAQ:APOP) 30 days 90 days 365 days Advanced Chart Get Cellect Biotechnology alerts:Sign Up Key Stats Today's Range N/A50-Day Range$7.54▼$13.4052-Week Range N/AVolume17,400 shsAverage Volume479,845 shsMarket Capitalization$12.87 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel. Read More Receive APOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellect Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address APOP Stock News HeadlinesWaterloo startup secures funding for innovative women's health deviceMay 23, 2025 | msn.comSphere Bio launches Cyto-Cellect Human IgG Kappa and Viability Assay Kit for efficient single-cell selectionMarch 31, 2025 | businesswire.comTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President Trump's Executive Order #14196 could not only save Social Security from collapse... ...but potentially increase benefits by up to 400%, according to legendary investor Louis Navellier.July 1 at 2:00 AM | InvestorPlace (Ad)Patent Term Adjustment and Double Patenting After In re CellectOctober 1, 2024 | reuters.comKrystal Biotech Inc.March 1, 2024 | wsj.comRaleigh/Durham Biotech NewsJune 23, 2023 | bizjournals.comSana Biotechnology Is Technically Overbought So Buy It LaterApril 19, 2023 | seekingalpha.comPiper Sandler says this biotech stock can outperform thanks to Alzheimer's treatmentApril 19, 2023 | cnbc.comSee More Headlines APOP Stock Analysis - Frequently Asked Questions How were Cellect Biotechnology's earnings last quarter? Cellect Biotechnology Ltd. (NASDAQ:APOP) announced its earnings results on Tuesday, November, 13th. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.56) by $0.02. When did Cellect Biotechnology's stock split? Shares of Cellect Biotechnology split on the morning of Tuesday, October 26th 2021.The 2-1 split was announced on Tuesday, October 26th 2021. The newly created shares were payable to shareholders after the closing bell on Tuesday, October 26th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. What other stocks do shareholders of Cellect Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cellect Biotechnology investors own include Elbit Systems (ESLT), Gilead Sciences (GILD), Protalix BioTherapeutics (PLX), Advanced Micro Devices (AMD), NVIDIA (NVDA), Acasti Pharma (ACST) and Corbus Pharmaceuticals (CRBP). Company Calendar Last Earnings11/13/2018Today7/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & Medical Instruments Sub-IndustryN/A Current SymbolNASDAQ:APOP CIK1671502 Webwww.cellect.co Phone(729) 974-1444Fax972-9767-8750Employees2,020Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio3.01 Quick Ratio3.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.77 per share Price / BookN/AMiscellaneous Outstanding Shares977,000Free FloatN/AMarket Cap$12.87 million OptionableNot Optionable Beta1.87 Social Links 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:APOP) was last updated on 7/1/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold prediction: $5,000/oz. or higher is comingThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellect Biotechnology Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cellect Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.